Novelfarma has an innovative product portfolio including treatment solutions in 4 fundamental treatment areas which are rare and genetic diseases (orphan medicines), pediatric diseases, digestive system diseases, and cancer diseases.
Additionally, develops products to use in struggle for medical aesthetics and obesity.
Novelfarma, develops numerous product to use in the treatment of the rare and genetic diseases as Wilson disease, Gaucher syndrome, Phenylketonuria, Cystic fibrosis, Homocystinuria, Hyperammoniemia (Urea Cycle Disorder), ALS (Amyotrophic Lateral Sclerosis).
Intended to digestive system, product studies of anti ulcer without PPI, irritable bowel syndrome, and spasmolytic has completed to bring them into use for patients.
Antidiarrheal medicines for infant and children that can be used safely even by newborns have developed for acute bronchitis medicines.
Novelfarma also has a wide product portfolio in the field of oncology. Many oncological products for topical, oral, and injectable use have developed.